QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Robinson, R. F Articles by Nahata, M. C Search for Related Content PubMed PubMed Citation Articles by Robinson, R. F Articles by Nahata, M. C

DRUG INFORMATION ROUNDS

Management of Botulism

Fellow, Pediatric Pharmacotherapy, College of Pharmacy, Ohio State University, Columbus, OH

Milap C Nahata, PharmD

Professor of Pharmacy and Division Chair, College of Pharmacy; Professor of Pediatrics and Internal Medicine, College of Medicine and Public Health, Ohio State University and Children's Hospital, Columbus, OH

Reprints: Milap C Nahata PharmD, College of Pharmacy, Ohio State University, 500 W. 12th Ave., Columbus, OH 43210-1291, FAX 614/292-1335

OBJECTIVE: To provide a concise review of the presentation and treatment of botulism.

DATA SOURCES: Searches of MEDLINE (1966–November 2001), tertiary references, and public and government Internet sites were conducted.

STUDY SELECTION: All articles and additional references from those articles were thoroughly evaluated.

DATA SYNTHESIS: Clostridium botulinum toxin blocks acetylcholine release in a dose-dependent fashion, resulting in acute symmetric diplopia, dysarthria, dysphonia, dysphagia, and possible neurologic sequelae despite the route of exposure (i.e., food-borne, wound, intestinal, inhalation). Disease secondary to genetically engineered C. botulinum may differ from that of inadvertent exposure. Present treatment is primarily supportive care, respiratory support, rapid decontamination, and antitoxin administration (i.e., trivalent, pentavalent, heptavalent antitoxin). Early initiation of antitoxin limits the extent of paralysis, but does not reverse it.

CONCLUSIONS: Supportive care and the use of antitoxin have been effective in the treatment of botulism from food-borne, intestinal, and wound exposure. However, the effectiveness of antitoxin in the treatment of inhaled C. botulinum has not been proven.

Key Words: botulism, Clostridium botulinum

www.theannals.com, DOI

This article has been cited by other articles:

				S. Chen and J. T. Barbieri Multiple Pocket Recognition of SNAP25 by Botulinum Neurotoxin Serotype E J. Biol. Chem., August 31, 2007; 282(35): 25540 - 25547. [Abstract] [Full Text] [PDF]

				S. Chen, J.-J. P. Kim, and J. T. Barbieri Mechanism of Substrate Recognition by Botulinum Neurotoxin Serotype A J. Biol. Chem., March 30, 2007; 282(13): 9621 - 9627. [Abstract] [Full Text] [PDF]

				L. M. Baddour, Z.-J. Zheng, D. R. Labarthe, and S. O'Connor Task Force I: Direct Cardiovascular Implications of Emerging Infectious Diseases and Biological Terrorism Threats J. Am. Coll. Cardiol., March 27, 2007; 49(12): 1380 - 1389. [Full Text] [PDF]

				D. P. Betten, R. B. Vohra, M. D. Cook, M. J. Matteucci, and R. F. Clark Antidote use in the critically ill poisoned patient. J Intensive Care Med, September 1, 2006; 21(5): 255 - 277. [Abstract] [PDF]

				S. Chen and J. T. Barbieri Unique Substrate Recognition by Botulinum Neurotoxins Serotypes A and E J. Biol. Chem., April 21, 2006; 281(16): 10906 - 10911. [Abstract] [Full Text] [PDF]

				M. R. Baldwin, W. H. Tepp, C. L. Pier, M. Bradshaw, M. Ho, B. A. Wilson, R. B. Fritz, E. A. Johnson, and J. T. Barbieri Characterization of the Antibody Response to the Receptor Binding Domain of Botulinum Neurotoxin Serotypes A and E Infect. Immun., October 1, 2005; 73(10): 6998 - 7005. [Abstract] [Full Text] [PDF]